



## COMPANY ANNOUNCEMENT

16 December 2024

No. 11-2024 – Inside information

### **ViroGates announces a reorganisation of its marketing and sales department and revises its guidance for the year**

**BIRKERØD, DENMARK**—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring the level of inflammation in individuals in health clinics and hospitals, announces that it will reorganise its business to strengthen its focus on the longevity and health segment and revises its financial guidance for 2024 accordingly.

An increased focus on sales to the health and longevity segment, including customers such as private laboratories, health clinics, etc., entails a different and more substantial marketing presence, and resources will be added to this area accordingly. In addition, ViroGates must revalue its direct sales presence in selected markets that have historically focused on sales to the acute care segment.

ViroGates has taken the first steps to implement the strategic change and is currently discussing it with the affected departments and individuals. As a result of the reorganisation, ViroGates expects some positions to be made redundant and will set aside severance costs in the 2024 financial statement.

Consequently, ViroGates is revising its financial guidance for the year 2024. ViroGates now expects revenue between DKK 4.5 and 5 million and an EBIT of DKK -14.5 to -15.5 million.

#### **For further information, please contact:**

*ViroGates A/S:*

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: [jk@virogates.com](mailto:jk@virogates.com)

*Certified Advisor:*

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: [ca@vhcorp.se](mailto:ca@vhcorp.se)

#### **About ViroGates**

ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals in health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit [www.virogates.com](http://www.virogates.com).